



Intravenous chemotherapy, the most common method of chemotherapy delivery, has 
several limitations including non-specific biodistribution, limited circulation time, and high 
susceptibility for multi-drug resistance. In the treatment of non-small cell lung cancer (NSCLC), 
administration of docetaxel (DX) and paclitaxel (PX) using a nanoparticle system offers 
numerous improvements to the standard of care therapies. This nanoparticle (NP) formulation, 
composed of Brij 78, Vitamin E TPGS, and a Miglyol 812 oil core (“BTM”) in addition to free 
drug, accomplishes passive targeting to the tumor site through the enhanced permeation and 
retention (EPR) effect. It also exhibits decreased drug resistance by circumvention of Pgp efflux 
pumps, and stealth properties through PEGylation.  However, the BTM NPs are limited by the 
low solubility of PX and DX in the Miglyol core (<10% wt/wt), low percent drug encapsulation 
within the NPs, and rapid drug release in-vivo with >90% of drug released in 1-2 hours.1 To 
overcome this limitation, lipid-ester prodrugs of DX and PX were synthesized to increase the 
solubility of DX and PX in the Miglyol core.  The solubility of the prodrugs in Miglyol was an 
order of magnitude greater that the DX and PX. More importantly, our results showed a marked 
increase in pro-drug accumulation at the tumor site compared to standard of care therapies of 
Taxotere® and Taxol®.2 A limitation of the lipidized prodrugs pertained to their slow rate of 
hydrolysis, resulting in poor release of the active free drug. The focus of current project is to 
reengineer the NP formulation to accommodate a free drug, as opposed to altering PX and DX to 
accommodate the oil core. A novel hydrophobic oil core consisting of N-octyl 2-pyrrolidone 
(NOP) was used. Both DX and PX are soluble in NOP at greater than 100% wt/wt. Furthermore, 
in-vitro cytotoxicity studies with A549, MRC5, HuVEC, and MLg cell lines showed placebo 
NPs made with an NOP core were less toxic than the placebo BTM NPs made with a 
biocompatible Miglyol core. Another advantage of the high solubility of PX, DX, and other 
drugs in NOP is that at high drug-loaded concentrations (50-100%), the increased viscosity 
allows NOP to be used as a depot, which could have use in intraperitoneal depot treatment of 















 Lung cancer claims more lives than any other cancer nationwide. Estimates for 2015 
predict lung and bronchus cancers will account for 28% and 26% of cancer-related deaths for 
men and women, respectively. Of these cancers, non-small cell lung cancer (NSCLC) composes 
83% of all cases. The standard of care (SOC) for advanced stage NSCLC patients, for which the 
5-year survival rate is only 4%, is chemotherapy, targeted therapies, or a combination of both.3 
Paclitaxel (PX) is an FDA-approved drug that interrupts cell division by preventing microtubule 
breakdown during mitosis. Currently, PX is administered intravenously in combination with 
carboplatin for treatment of NSCLC.4  
The shift from intravenous administration of free drug to targeted therapies aims to 
reduce non-specific toxicity and increase therapeutic efficacy by limiting the amount of drug 
distributed to healthy tissue.  Nanoparticles act as a vehicle for drug delivery. The particle 
shields the drug from healthy tissue during transport and increases drug accumulation at the 
tumor via the Enhanced Permeation and Retention (EPR) effect. The first FDA-approved PX 
nanoparticle formulation, Abraxane ®, delivers PX as an albumin-bound particle, and was shown 
to deliver 1.5 times the maximum tolerated dose (MTD) of free PX without increased non-
specific toxicity.5 However, the improvement in rates of progression free survival and overall 
survival in phase III trials were not shown to be statistically significant.6 Incorporation of PX 
into nanoparticles, such as Abraxane, has been limited by low solubility of PX in most 
hydrophobic solvents. This leads to low dosing and rapid release of PX.  Therefore, there is a 
need for a formulation that can more efficiently dose PX and provide a higher therapeutic index 
(ratio of toxicity to the tumor to toxicity to the host) than the current SOC therapies.2 
 For some cancers originating in the peritoneal cavity, such as ovarian and pancreatic 
cancers, new targeted therapies include intraperitoneal (IP) injections. Such cancers are often 
characterized by solid, dense tumors with limited vasculature and high interstitial pressure. These 
characteristics hinder intravenously administered drugs from entering the tumor, and 
subsequently from spreading throughout the tumor. IP injection therapy offers delivery of drug 
directly at the tumor site, both increasing drug penetration of the tumor and reducing non-
specific toxicity. Similar to nanoparticles, these therapies are limited by low dosing ability, rapid 
release profiles, and excipient toxicity. Currently, IP therapy is used to treat debulked stage III 
ovarian cancer patients who have a small residual tumor. However, many complications arise 
due to the use of an IP catheter, such as infection, fever, and peritoneal tissue damage.7 
Therefore, a slow-releasing, one-time injectable depot can be an ideal alternative.  
 The solvent N-octyl 2-pyrrolidone (NOP) has demonstrated superior solvent ability for 
both PX and docetaxel (DX) (>100% wt/wt). The use of NOP as an oil core in a nanoparticle 
will allow for therapeutic dosing of the drug without high dosing of excipients. Preliminary 
studies have shown that NOP can successfully form an appropriately sized (approximately 90-
nm) and unimodal distribution of lipid nanoparticles (NPs), incorporating the biocompatible 
excipients of Brij 78 and Vitamin E TPGS, with Brij 78-PEG1000 for stealth properties. 
Furthermore, when loaded with PX at higher concentrations (50-100% wt/wt), the NOP/PX 
solution becomes a viscous gel that has demonstrated potential for use as an IP injected depot.  
 Materials and Methods:  
Materials: 
 Polyoxyl 20-stearyl ether (Brij 78) was purchased from Uniqema (Wilmington, DE, 
USA). D-alpha-tocopheryl polyethylene glycol-1000 succinate (Vitamin E TPGS) was purchased 
from Eastman Chemicals (Kingsport, TN, USA). Miglyol 808 and Miglyol 812 were purchased 
from Sasol (Witten, Germany). N-octyl 2-pyrrolidone (NOP) was purchased from Sigma Aldrich 
(St. Louis, MO, USA). Paclitaxel (PX) was purchased from LC Laboratories (Woburn, MA, 
USA). Isopropanol (IPA) was purchased from Fischer Scientific (Fair Lawn, NJ, USA).  
 
Determination of drug solubility in NOP and Miglyol 
 The solubility of multiple drugs and prodrugs was tested in three solvents: NOP, Miglyol 
808, and Miglyol 812. Each solubility test began with addition of 10 mg of drug and 100 mg of 
solvent to a 7-mL glass vial. Solutions were obtained by vortexing and/or gently heating the 
sample. Increased amounts of drug or solvent were added in 10 mg and 100 mg increments, 
respectively, as needed.  
 
Formation of Placebo NOP NPs 
 All excipients (Brij 78, Vitamin E TPGS, Brij 78-PEG1000) were weighed into a 7-mL 
clear glass vial, followed by addition of 70:30 NOP:Miglyol 808. The vial was then placed in a 
65°C water bath until to allow all excipients to melt, followed by vortexing to create a 
homogenous mixture. Finally, 1-mL of warm DI H2O was added to the vial and the 
microemulsion was formed by stirring at 1000 RPM at room temperature for 20 minutes.  
 
Characterization of NOP Placebo NPs 
The particle diameter and zeta potential of NOP placebo NPs were characterized using a 
Malvern Zetasizer Nano ZS. Samples were diluted by a hundred-fold and a thousand-fold in 
phosphate-buffered saline (PBS) to test stability. The nanoparticles were also lyophilized using 
an AdVantage 2.0 BenchTop Lyophilizer and tested for particle size after reconstitution in DI 
water.  
Cytotoxicity of NOP and Placebo NOP NPs 
 The cytotoxicity of NOP and NOP-based placebo NPs in A549 human lung 
adenocarcinoma cells, MLg healthy mouse lung cells, MRC5 healthy human lung cells, and 
HuVEC healthy human endothelial cells was determined using a CellTiter-Glo Luminescent Cell 
Viability Assay ® and compared to the placebo BTM NPs. Cells were incubated with NOP, 
NOP placebo NPs, and BTM placebo NPs at a series of different concentrations ranging from 
30.5 ng/mL to 500 μL/mL for 72hrs without replenishment of media.  
 
Release Study and Quantification of PX-loaded NOP Depot 
The PX/NOP solution (x mg) was injected into a 1cm3 foam support using an autopipet 
fitted with a 22½-gauge needle. The release medium consisted of 10 mL of either DI H2O or a 
50:50 ratio of DI H2O and isopropyl alcohol (IPA) in a 20 mL glass scintillation vial. At each 
time point, the support was removed and placed into a new vial containing fresh medium. The 
release medium was removed using a rotary evaporator and drug was reconstituted in 1 mL of 
acetonitrile (ACN). The amount of drug was quantified using high performance liquid 
chromatography (HPLC) using a Finnigan Surveyor HPLC system (Thermo Finnigan San Jose, 
CA) with a Photodiode Array (PDA) plus detector, autosampler, and LC pump plus with an 
Inertsil® ODS-3 column (4μm, 4.6×150mm, [GL Sciences, Torrance, CA]) at 40°C. 
Chromatographic separation was achieved by gradient elution using mobile phase consisting of 
0.1% triflouroacetic acid (TFA) in water and 0.1% (TFA) in acetonitrile (ACN) (95:5 v/v). The 
flow rate was 1.0 mL/minute and the total run time was 28 minutes for each 25 μL injection. The 
wavelength was set to 249 nm for peak analysis. 
Results: 
  
Determination of drug solubility in NOP and Miglyol  
NOP was a superior solvent for all drugs and prodrugs tested, most notably DX and PX 
(Table 1). These results indicate that a nanoparticle composed of an NOP core would have the 
potential to carry a much higher dose of PX and DX than existing NP formulations, such as the 
BTM NP formulation in which Miglyol 812 is the oil core.  
 
Table 1: Solubility of Various Drugs and Prodrugs in NOP, Miglyol808, Miglyol812 (mg/mL) 
Solubility testing was done visually, and solubility of drugs in solvents is reported in mg/mL.  
 
Formation of NOP Placebo NPs 
 The NOP placebo NPs were fabricated as described above using NOP/Miglyol 812 
(70:30 wt/wt) as the oil phase, and Brij78, Vitamin E TPGS, and Brij78-PEG1000 as surfactants. 
This formulation was optimized through testing of various ratios of NOP:Miglyol 812, 
surfactant, and levels of PEGylation. For each trial, the particle size distribution and stability 
upon dilution was examined. A ratio of 70:30 NOP:Miglyol 812 as the oil core produced the 
most stable microemulsion (Table 2). A ratio of 2:1 Brij78:Vitamin E TPGS, as used in the BTM 
formulation, was initially used and proved to be successful with the NOP placebo NPs. No 
significant difference was observed at various levels of PEGylation. Equal parts of Brij78 and 
Brij78-PEG1000 was chosen for use in further experiments. The final formulation is shown in 
Table 3 below. 
 
 Docetaxel Paclitaxel Camptothecin SN38 C12:DX C18:DX Br-C16:DX Br-C16:PX 
NOP 1000 1000 < 21.4 59.8 1026 684 256 342 
Miglyol 
808 
42.7 27.7 < 5.63 < 0.74 84.0 84.0 568 568 
Miglyol 
812 
42.7 27.7 < 5.63 < 0.47 84.0 84.0 568 568 
Table 2: Optimization of NOP Placebo NP Formulation 
Quantities of Brij 78 and TPGS are amounts needed to form microemulsion 
 









Characterization of NOP Placebo NPs 
 The particle diameter and zeta potential of the NOP placebo NPs was measured at various 
dilutions (Table 4). The particles exhibited a particle diameter of approximately 90 nm and a zeta 
potential of -7.9 mV.  







Particle sizes obtained using Malvern Zetasizer Nano ZS. PI is the abbreviation for  




Cytotoxicity of NOP and NOP-based Placebo NPs  
An in vitro cytotoxicity study for NOP, placebo NOP NPs, and placebo BTM NPs was 
conducted with A549, MLg, and MRC5 cell lines using a CellTiter-Glo Luminescent Cell 
Viability Assay. As shown in Figure 1, both pure NOP and NOP placebo NPs were significantly 
less toxic than the placebo BTM NPs. Since NOP has only been used for veterinary purposes as 
of yet, this study was the first to examine its potential biocompatibility. From these results, it can 
be concluded that the NOP NPs do not introduce any additional excipient toxicity compared to 
the BTM NPs, a formulation whose biocompatibility has already been demonstrated in previous 















90:10 225 25 80 40 1:1000 NA NA 
80:20 200 50 72 36 1:1000 126.1 1.750 
70:30 175 75 49 24.5 1:1000 95.7 0.302 
Ingredient Function Concentration (mg/mL) 
70:30 NOP:Miglyol 812 Oil 192.3 
Brij 78 Surfactant 19.2 
Vitamin E TPGS Surfactant 19.2 
Brij 78 – PEG1000 Stealth 19.2 
 1:100 Dilution (PBS) 1:1000 Dilution (PBS) 
Sample # Unimodal (nm) PI Unimodal (nm) PI 
1 94.86 0.231 88.90 0.257 
2 93.25 0.246 89.24 0.259 
















Figure 1: Cytotoxicity Assay of NOP and NOP NPs 
Concentrations reflect the concentration of solvent 










































































































































































































































Release studies testing both 
50% PX-loaded NOP and 75% PX-
loaded NOP as potential depots 
were performed using a 
polyurethane foam support to 
contain the depot and imitate in 
vivo injection site. For these 
release studies 50:50 IPA:H2O was 
used as the release medium. This 
medium was chosen due to the low 
water solubility of PX (<1 
μg/mL).8  The medium was 
replenished at each time point to 
ensure that sink conditions were 
maintained at all times. The lower 
limit of quantification for PX 
generated from the HPLC standard 
curve was 244 ng/mL, which 
represents less than 0.01% release from the depot. The results showed a large burst release of 
43.4 + 3.3% of the total encapsulated drug within the first six hours of the study, followed by an 
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Release Study and Quantification of UNC3230A-loaded NOP Depot 
 A potential new 
chemotherapeutic, UNC 3230-A, 
was also tested in an NOP depot. 
The small-molecule drug targets 
the lipid kinase PIP5K1C, a target 
in the treatment of many diseases, 
including prostate cancer.9 The 
solubility of UNC 3230-A in NOP 
was 35% wt/wt. The release study 
was also performed using a foam 
support and 50:50 IPA:DI H2O as 
the release medium. The medium 
was replenished at each time point 
to ensure that sink conditions were 
maintained at all times. The lower 
limit of quantification for UNC 
3230-A generated from the 
standard curve was 488 ng/mL, 
which represents less than 0.01% release from the depot. Results from this study demonstrated a 
large burst release of 44.5 + 13.1% of the total encapsulated drug within the first six hours of the 
study, followed by continued release over the remainder of the 4-week period (Figure 3) for a 
final cumulative release of 83.9 + 3.4%. To determine if the release of UNC 3230-A from NOP 
could exhibit a slower burst release and a zero-order release kinetics following the burst release, 
the release medium was changed to 25:75 IPA:DI H2O and a second release study was 
performed. The results from this study showed that the depot exhibited a smaller burst release of 
8.28 + 0.22% of the total encapsulated drug in the first eight hours of the study, followed by an 
additional 10.1 + 0.8% release steadily over the remaining 17 days (Figure 4).  
 
Discussion: 
 The solubility of docetaxel (DX) and paclitaxel (PX) in N-octyl 2-pyrrolidone (NOP) 
(1000 mg/mL) is significantly greater than in Miglyol 808 and 812 (42.7 mg/mL). Existing 
nanoparticle (NP) formulations involving Taxols, such as the “BTM” formulation involving 
Miglyol 808, are limited by low drug encapsulation and the use of lipidized prodrugs to 
overcome this limitation.  The superior solvent ability of NOP offers potential for a nanoparticle 
formulation with high dosing of free drug. This is preferable over a prodrug that requires 
hydrolysis at the tumor site to release the active drug. 
 Optimization of a NOP placebo NPs yielded a formulation that maintained the use of 
biocompatible surfactants Brij 78 and Vitamin E TPGS. In addition, there was also flexibility to 
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Figure 4: Cumulative % Release of UNC3230/NOP Depot 
in 50:50 IPA:DI H20
(approximately 90 nm) were stable upon a hundred-fold and a thousand-fold dilution, and 
showed low polydispersity (< 0.260) when analyzed for particle diameter.  
 Cytotoxicity of pure NOP and the placebo NOP NPs was examined relative to the 
placebo BTM NPs using four different cell lines: A549, MRC5, MLg, and HuVEC. The results 
showed that, generally, pure NOP was the least toxic to cells at a given concentration, followed 
by the placebo NOP NPs, and placebo BTM NPs.  Increased toxicity of NPs over pure NOP is 
likely due to excipients (i.e. surfactants). The similar profiles of placebo NOP NPs and placebo 
BTM NPs are promising for the use of NOP in vivo. BTM NPs have been previously studied and 
shown to be biocompatible, whereas this was the first toxicity assay for NOP and NOP NPs. 
 Initial experiments in which the placebo NOP NPs were loaded with paclitaxel were not 
successful. We hypothesize that the high affinity of PX for NOP may have resulted in a 
breakdown of the NPs as the surfactants were forced to compete for solubility in NOP. One way 
to overcome this is by using a stabilizing agent, such as a polymer which could help form a 
stable drug-loaded formulation. These studies are currently underway.  
 Pure PX-loaded NOP was tested for potential use as an injectable, intraperitoneal depot. 
The viscous nature of 50+% wt/wt PX/NOP allows for injection while solidification upon 
contact with water allows for a solid, stationary depot. Both 50% and 75% wt/wt PX/NOP were 
tested as depots and demonstrated a high burst release profile, releasing 43.4 + 3.3% within six 
hours and only an additional 0.2% release over the remainder of the 4-week period. The addition 
of a biodegradable polymer to control drug release from a depot is a proven technique, and is the 
next step in this optimization process.10 A second drug, UNC 3230-A, was introduced as a depot 
candidate with a high solubility of 350 mg/mL in NOP. This 35% wt/wt UNC3230A/NOP depot 
was tested in two media (list here), each indicating a considerable burst release and subsequent 
steady release over time. While this formulation would also benefit from the addition of a 
polymer, it would likely not require as much modification as the PX formulation. It is clear that 
both PX and UNC 3230-A depots warrant further studies and future in vivo work, as they 





 As a superior solvent, NOP has been investigated for use as a nanoparticle oil core for the 
treatment of NSCLC and as a depot base for the treatment of cancers of the peritoneal cavity. 
Existing nanoparticle formulations involving PX have been limited by the low solubility of PX in 
most solvents. NOP has been shown to both solubilize DX and PX at 100% wt/wt and form a 
stable and non-cytotoxic placebo nanoparticle. At high drug saturations, >50% wt/wt, NOP 
becomes a viscous gel that shows substantial potential as a depot. Existing IP therapy is limited 
by dosing and reliance on catheters for continuous administration. Release studies in vitro 
demonstrate significant drug release with release profiles that can be further managed by 
addition of biodegradable polymers, a strategy we are currently investigating. 
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